Biogen (BIIB) Long-Term Deferred Tax (2017 - 2026)

Biogen (BIIB) has reported Long-Term Deferred Tax for 10 consecutive years, with $238.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 22.54% year-over-year to $238.2 million; the TTM figure through Mar 2026 stood at $238.2 million (down 22.54% YoY), while the FY2025 annual figure was $292.5 million, down 9.78% from the prior year.
• Long-Term Deferred Tax came in at $238.2 million for Q1 2026 at Biogen, down from $292.5 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $1.3 billion in Q1 2022, with the low at $238.2 million in Q1 2026.
• Average Long-Term Deferred Tax over 5 years is $819.5 million, with a median of $928.6 million recorded in 2023.
• Across the five-year window, Long-Term Deferred Tax climbed 0.19% in 2022 and plunged 67.75% in 2025, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $1.2 billion in 2022, then dropped by 24.28% to $928.6 million in 2023, then tumbled by 65.09% to $324.2 million in 2024, then decreased by 9.78% to $292.5 million in 2025, then slipped by 18.56% to $238.2 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $238.2 million, $292.5 million, and $312.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.